Azacitidine as maintenance therapy in pediatric de novo acute myeloid leukemia

BackgroundRelapse remains a major challenge in pediatric acute myeloid leukemia (AML), particularly in patients ineligible for hematopoietic stem cell transplantation (HSCT). Hypomethylating agents like azacitidine are hypothesized to target residual disease, but their efficacy and safety as mainten...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Chunping Wu, Chunxia Cai, Mei Li, Nainong Li, Yongzhi Zheng, Hao Zheng
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2025-12-01
סדרה:	Frontiers in Immunology
נושאים:	pediatric AML azacitidine maintenance measurable residual disease molecular relapse risk stratification
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1696125/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!